Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Alaunos Therapeutics Inc
TCRT | US
2.00
USD-0.28
-12.28%
TCRT | US
Loading StockChartView...
About Alaunos Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
08/06/2026
Close
2.00
Open
2.29
High
2.29
Low
2.00
Alaunos Therapeutics Inc. a clinical-stage oncology-focused cell therapy company develops adoptive TCR engineered T-cell therapies. It develops TCR Library which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS TP53 and EGFR from its TCR library for the treatment of non-small cell lung colorectal endometrial pancreatic ovarian and bile duct cancers; hunTR a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology Inc. and changed its name to Alaunos Therapeutics Inc. in January 2022. Alaunos Therapeutics Inc. was founded in 2003 and is headquartered in Houston Texas.
View LessTCRT | US
Risk
92.9
Sharpe
-0.34
Luna's Score
31/100
Recommendation
Sell
Luna says (TCRT | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
129.6%1 month
92.9%3 months
63.1%6 months
75.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.94
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-3.55
Ent. to rev.
724.36
PEG
-
Other Fundamentals
EBITDA
-12.58M
MarketCap
3.20M
MarketCap(USD)
3.20M
Div. yield
-
Op. margin
-29.15K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-150.50
Short ratio
4.84
Short perc.
9.48
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.09
Range1M
1.09
Range3M
1.65
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.61
Price X volume
63.59K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.55 | 0.53 | Cheaper |
| Ent. to Revenue | 724.36 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.94 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 63.15 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 3.20M | 3.66B | Emerging |
